Recombinant Human ALX4 293 Cell Lysate

• Cat.No.: ALX4-8889HCL

Specification

• Description: Antigen standard for ALX homeobox 4 (ALX4) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ALX4 ALX homeobox 4 [ Homo sapiens ]
• Official Symbol: ALX4
• Synonyms: ALX4; ALX homeobox 4; aristaless like homeobox 4 , parietal foramina 2 , PFM2; homeobox protein aristaless-like 4; FPP; KIAA1788; PFM; aristaless-like homeobox 4; homeodomain transcription factor ALX4; FND2
• Gene ID: 60529
• mRNA Refseq: NM_021926
• Protein Refseq: NP_068745
• MIM: 605420
• UniProt ID: Q9H161
• Chromosome Location: 11p11.2
• Function: DNA binding; HMG box domain binding; protein heterodimerization activity; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity

Reviews

01/03/2019

Compatibility with small sample volumes for limited samples.

03/05/2018

High specificity in protein target identification.

01/04/2017

Stable and reliable reagents for reproducible results.

Q&As

What are the protein-protein interactions of ALX4, and how do these interactions contribute to its function in regulating gene expression and cellular processes?

ALX4 interacts with various co-regulatory proteins and transcription factors, forming complexes that modulate gene expression and cellular processes critical for embryonic development.

What are the DNA binding motifs recognized by ALX4, and how do they contribute to its transcriptional regulatory activity?

ALX4 recognizes specific DNA binding motifs, such as homeobox motifs, and binds to regulatory regions of target genes to regulate their transcriptional activity.

What are the functional consequences of gain-of-function or loss-of-function mutations in ALX4, and how do they impact embryonic development and tissue morphogenesis?

Gain-of-function or loss-of-function mutations in ALX4 can disrupt normal embryonic development, leading to craniofacial abnormalities, limb defects, or skeletal malformations.

What are the epigenetic modifications associated with ALX4 binding sites, and how do they influence its transcriptional activity and downstream gene expression?

ALX4 binding sites are associated with specific epigenetic modifications, such as DNA methylation or histone modifications, which contribute to the regulation of ALX4-mediated transcriptional activity.

How does ALX4 interact with signaling pathways, such as BMP, Wnt, or FGF signaling, to modulate gene expression and cellular behaviors during embryonic development?

ALX4 integrates with signaling pathways, such as BMP, Wnt, or FGF signaling, to modulate gene expression and influence cellular behaviors during embryogenesis.

Can ALX4 be targeted pharmacologically or genetically to modulate its activity, and what are the potential therapeutic implications?

Pharmacological or genetic modulation of ALX4 activity may have therapeutic implications for craniofacial disorders, skeletal dysplasias, or regenerative medicine, but further studies are needed to explore these possibilities.

How does ALX4 interact with other transcription factors and co-regulators to form transcriptional complexes that control gene expression and cellular fate during embryonic development?

ALX4 forms transcriptional complexes with other transcription factors and co-regulators, such as MSX1 or RUNX2, to coordinate gene expression programs essential for craniofacial development, skeletal patterning, and limb morphogenesis.

What is the spatiotemporal expression pattern of ALX4 during embryonic development, and in which tissues and cell types is it predominantly expressed?

ALX4 exhibits a dynamic spatiotemporal expression pattern during embryonic development, with prominent expression in craniofacial structures, limb buds, and axial skeleton.

How does ALX4 regulate cell proliferation, differentiation, and migration during embryogenesis, and what are the underlying molecular mechanisms?

ALX4 regulates cell proliferation, differentiation, and migration during embryogenesis through various molecular mechanisms, including interactions with cell cycle regulators, morphogen gradients, or cytoskeletal components.

What are the downstream target genes regulated by ALX4, and how does it modulate their expression to influence cellular processes during development?

ALX4 regulates the expression of genes involved in craniofacial development, skeletal patterning, and limb formation, including those encoding transcription factors, extracellular matrix components, or signaling molecules.